LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

Home・Aktien・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Open

Branche Gesundheitswesen

7.94 -0.13

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

7.88

Max

8.01

Schlüsselkennzahlen
By Trading Economics
EPS	-0.172
Gewinnspanne	-66.092
Angestellte	536

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+93.56 upside

Dividenden
By Dow Jones
Nächstes Ergebnis	31. Okt. 2024

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	41M 990M
Vorheriger Eröffnungskurs	8.07
Vorheriger Schlusskurs	7.94

Nachrichtenstimmung

By Acuity

50%

114 / 365 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

6.1 / 7.65 Unterstützung & Widerstand

BioCryst Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Sept. 2024, 23:40 UTC

Heiße Aktien

Stocks to Watch: Intel, Netcapital, Microsoft

16. Sept. 2024, 22:56 UTC

Akquisitionen, Fusionen, Übernahmen

Xero Bolsters Customer Insights With $70 Million Acquisition of Syft

16. Sept. 2024, 19:21 UTC

Akquisitionen, Fusionen, Übernahmen

Vista Equity Partners, Blackstone Close to $8 Billion Buyout Deal for Smartsheet, Reuters Reports

16. Sept. 2024, 22:47 UTC

Market Talk

Auckland International Airport's August Traffic Underwhelms -- Market Talk

16. Sept. 2024, 22:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16. Sept. 2024, 22:47 UTC

Market Talk

Global Equities Roundup: Market Talk

16. Sept. 2024, 22:41 UTC

Akquisitionen, Fusionen, Übernahmen

Xero Bolsters Customer Insights With $70 Mln Acquisition of Syft

16. Sept. 2024, 22:37 UTC

Akquisitionen, Fusionen, Übernahmen

Santos to Own 36.5% of Bayu-Undan Following Sale, Purchase Deed

16. Sept. 2024, 22:36 UTC

Akquisitionen, Fusionen, Übernahmen

Santos: Production Sharing Contract for Bayu-Undan to Cease at End-June 2026 or When Output Stops if Earlier

16. Sept. 2024, 22:35 UTC

Akquisitionen, Fusionen, Übernahmen

Santos: Bayu-Undan JV Executes Sale, Purchase Deed to Transfer 16% Stake in Upstream Project to Timor GAP

16. Sept. 2024, 22:34 UTC

Akquisitionen, Fusionen, Übernahmen

Xero: Syft's More Than 70 Employees Will Transition With Acquisition

16. Sept. 2024, 22:31 UTC

Akquisitionen, Fusionen, Übernahmen

Xero: Syft Will Still Be Available as a Standalone Offering

16. Sept. 2024, 22:30 UTC

Akquisitionen, Fusionen, Übernahmen

Xero: Syft Is Used in More Than 80 Countries

16. Sept. 2024, 22:30 UTC

Akquisitionen, Fusionen, Übernahmen

Xero Expects to Complete Acquisition of Johannesburg-Based Syft in 3Q FY25

16. Sept. 2024, 22:29 UTC

Akquisitionen, Fusionen, Übernahmen

Xero to Pay Balance in Earnouts, Restricted Stock Over Three Years

16. Sept. 2024, 22:28 UTC

Akquisitionen, Fusionen, Übernahmen

Xero Will Pay US$40 Mln Up Front Including US$10 Mln in Shares

16. Sept. 2024, 22:28 UTC

Akquisitionen, Fusionen, Übernahmen

Xero Will Embed Syft to Accelerate Insights, Analytics Offerings

16. Sept. 2024, 22:27 UTC

Akquisitionen, Fusionen, Übernahmen

Xero: Syft Services Accountants, Bookkeepers, Small Businesses

16. Sept. 2024, 22:27 UTC

Market Talk

Auckland Airport Raises More Equity Than Citi Expected -- Market Talk

16. Sept. 2024, 22:26 UTC

Akquisitionen, Fusionen, Übernahmen

Xero: Syft Is a Cloud-Based Reporting, Insights, Analytics Platform

16. Sept. 2024, 22:26 UTC

Akquisitionen, Fusionen, Übernahmen

Xero Acquiring Syft Analytics for Up to US$70 Million

16. Sept. 2024, 22:08 UTC

Top News

Microsoft Boosts Dividend, Authorizes Up to $60B of Buybacks

16. Sept. 2024, 21:17 UTC

Top News

Intel CEO Lays Out New Steps to Cut Costs and Bolster Chip-Making Division -- 2nd Update

16. Sept. 2024, 21:16 UTC

Ergebnisse

Tech Growth Is Slowing. These 6 Companies Could Still Shine. -- Barrons.com

16. Sept. 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16. Sept. 2024, 20:46 UTC

Top News

Amazon Tells Workers to Return to Office Five Days a Week -- 2nd Update

16. Sept. 2024, 20:34 UTC

Top News

Intel CEO Lays Out New Steps to Cut Costs and Bolster Chip-Making Division -- Update

16. Sept. 2024, 20:28 UTC

Top News

Boeing Freezes Hiring, Delays Pay Raises as Strike Worsens Finances -- 2nd Update

16. Sept. 2024, 20:19 UTC

Top News

Dow Hits Record as Investors Bet on Bigger Fed Cut -- WSJ

16. Sept. 2024, 20:07 UTC

Top News

Intel CEO Lays Out New Steps to Cut Costs and Bolster Chip-Making Division -- WSJ

Peer-Vergleich

Kursveränderung

BioCryst Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

93.56% Vorteil

12-Monats-Prognose

Durchschnitt 15.33 USD 93.56%

Hoch 30 USD

Tief 7 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für BioCryst Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

Buy

Halten

Sell

Basierend auf 9 Analysten, die in den letzten 3 Monaten Aktienbewertungen für BioCryst Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

6.1 / 7.65Unterstützung & Widerstand

Recent bullish events outweigh bearish events.

All events are bullish.

All events are bearish.

Stimmung

By Acuity

114 / 365 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc. discovers oral and small-molecule medicines that treat rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The Company has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.